| Serial Number | 79379326 |
| Word Mark | ENDOPORE |
| Filing Date | Tuesday, July 25, 2023 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, April 8, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 8, 2025 |
| Goods and Services | Pharmaceutical preparations for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for gene editing; veterinary preparations for gene editing; pharmaceutical preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; veterinary preparations for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical preparations for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for gene editing; pharmaceutical substances for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical substances for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical compositions and preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer |
| Goods and Services | Compilation of information into computer databases in the medical field |
| Goods and Services | Medical services; medical analysis for the diagnosis and treatment of persons; pharmacy advice, namely, preparation of prescriptions in pharmacies and providing medical advice related to pharmaceutics; advisory services relating to health; advisory services relating to medical services; health care, namely, arranging of medical treatment; consultancy relating to health care; health advice and information services; health care; health care services; health centres being health clinic services; health clinic services; information services relating to health care; medical information retrieval services; health care, namely, medical treatment services; medical health assessment services; health care, namely, preparation of reports relating to health care matters; professional consultancy relating to health; providing health information; provision of health care services; provision of medical services; provision of medical information relating to medical practitioners; provision of medical information relating to medical specialists; services for the provision of medical care information; information, advisory and consultancy services relating to all of the aforesaid |
| Goods and Services | Scientific and technological services, namely, scientific research, technological research, and research and design, all in the fields of intracellular delivery of drugs, gene editing, intracellular delivery of therapeutic substances focused on the development of RNA therapies, intracellular delivery of therapeutic substances focused on non-viral delivery technology, intracellular delivery of nucleic acids, intracellular delivery of proteins, intracellular delivery of peptides, and intracellular delivery of small molecules; research services in the fields of intracellular delivery of drugs, gene editing, intracellular delivery of therapeutic substances focused on the development of RNA therapies, intracellular delivery of therapeutic substances focused on non-viral delivery technology, intracellular delivery of nucleic acids, intracellular delivery of proteins, intracellular delivery of peptides, and intracellular delivery of small molecules; clinical trials, namely, scientific research in the nature of conducting clinical trials for others; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; medical research laboratories; medical research laboratory services; medical research; medical research services; pharmaceutical drug development services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of vaccines and medicines; research of pharmaceuticals; research relating to medicines; research relating to pharmaceuticals; scientific investigations for medical purposes; scientific research and development; scientific research in the field of pharmacy; medical research, namely, services for assessing the efficacy of pharmaceuticals; information, advisory and consultancy services relating to all of the aforesaid |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 22, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 22, 2023 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 22, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 22, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | VITARKA THERAPEUTICS LTD |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | VITARKA THERAPEUTICS LTD |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Tuesday, September 26, 2023 | APPLICATION FILING RECEIPT MAILED |
| Thursday, September 21, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, September 22, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, March 27, 2024 | ASSIGNED TO EXAMINER |
| Saturday, March 30, 2024 | NON-FINAL ACTION WRITTEN |
| Sunday, March 31, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Friday, July 19, 2024 | LIMITATION OF GOODS RECEIVED FROM IB |
| Tuesday, September 10, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, September 10, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, September 10, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, April 17, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Wednesday, April 17, 2024 | REFUSAL PROCESSED BY MPU |
| Wednesday, May 8, 2024 | REFUSAL PROCESSED BY IB |
| Friday, August 2, 2024 | LIMITATION OF GOODS RECEIVED FROM IB |
| Tuesday, September 10, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, September 10, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, September 10, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, September 10, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, September 10, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, October 14, 2024 | FINAL REFUSAL WRITTEN |
| Monday, October 14, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Monday, October 14, 2024 | FINAL REFUSAL E-MAILED |
| Thursday, February 20, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Thursday, November 14, 2024 | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Wednesday, January 15, 2025 | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Thursday, February 20, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Friday, March 14, 2025 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, March 14, 2025 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, March 14, 2025 | EXAMINERS AMENDMENT E-MAILED |
| Friday, March 14, 2025 | EXAMINER'S AMENDMENT ENTERED |
| Friday, March 14, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 2, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 8, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 8, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Saturday, March 8, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |